Former Emisphere investors sue over 'ill-timed' $1.8B sale to Novo Nordisk

With Novo Nordisk's diabetes med Rybelsus on the ascent, the Danish drugmaker last year snapped up drug delivery specialist Emisphere Technologies, which was responsible for the med's unique oral delivery route. But now former Emisphere investors aren't happy with their share of the payout.